ASH 2025 | Key highlights in lymphoma and CLL

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lymphocytic leukemia (CLL) from the meeting. 

Brody highlighted several presentations on approved and novel immunotherapies for patients with lymphoma and CLL. He discussed the significant progress made in the treatment of B-cell non-Hodgkin lymphoma (NHL). He also discussed the historically poor outcomes in patients with T-cell lymphoma and highlighted some of the novel therapies presented at ASH for this patient population. 

Key highlights 

• Encouraging early data were presented on bicistronic/bispecific chimeric antigen receptor (CAR) T-cell therapies in patients with B-cell NHL.
• Bispecific antibodies data were a major focus, such as the primary results from the phase III EPCORE FL-1 trial (NCT05409066) of epcoritamab in combination with lenalidomide + rituximab in patients with second-line (2L) follicular lymphoma (FL).
  • The Lymphoma Hub also spoke to Lorenzon Falchi, who discussed the latest results from the EPCORE FL-1 trial, as presented at ASH.
• Novel bispecific antibodies targeting CD19 and CD3 were highlighted, such as surovatamig in patients with relapsed/refractory (R/R) B-cell lymphoma.
• Emerging targeted therapies for patients with T-cell lymphoma were presented, such as soquelitinib, a selective interleukin-2-inducible T-cell kinase (ITK) inhibitor.
• Advances in CD5-targeting CAR T-cell therapies were reported, including results from the phase I VIPER 101 trial of dual-population autologous CD5-deleted anti-CD5 CAR T-cell therapy and interim results from a phase II trial of MB-105 – both in patients with R/R T-cell lymphoma.

Brody concluded by highlighting the progress in both B-cell and T-cell lymphomas, and the current emphasis on developing new immunotherapies.